Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 09:27, 19 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - updated 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit		Latest revision as of 15:35, 12 September 2024 edit undoRotcaeroib (talk | contribs)Extended confirmed users879 editsm Wording and grammar
(37 intermediate revisions by 25 users not shown)
Line 1:		Line 1:
	{{chembox		{{chembox
			| Verifiedfields = changed
⚫	| verifiedrevid = 427891725
			| Watchedfields = changed
⚫	|Name=Sophoraflavanone G
		⚫	| verifiedrevid = 445641469
	|ImageFile1=Clip_image002.PNG
	|ImageName=Chemical structure of Sophoraflavanone G		| Name = Sophoraflavanone G
		⚫	| ImageFile1 = Sophoraflavanone G.svg
⚫	|IUPACName=(2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8--2,3-dihydro-4H-chromen-4-one
			| ImageName = Chemical structure of sophoraflavanone G
		⚫	| IUPACName = (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8--2,3-dihydro-4H-chromen-4-one
	|Section1={{Chembox Identifiers		|Section1={{Chembox Identifiers
			| CASNo = 97938-30-2
	| UNII_Ref = {{fdacite|correct|FDA}}
		⚫	| CASNo_Ref = {{cascite|changed|CAS}}
	| ChEBI_Ref = {{ebicite|correct|EBI}}		| ChEBI_Ref = {{ebicite|correct|EBI}}
	| ChEBI ID = 50209		| ChEBI = 50209
			| ChEMBL = 243148
	| KEGG_Ref = {{keggcite|correct|kegg}}
⚫	| InChI = 1S/C25H28O6/c1-13(2)5-6-15(14(3)4)9-18-20(28)11-21(29)24-22(30)12-23(31-25(18)24)17-8-7-16(26)10-19(17)27/h5,7-8,10-11,15,23,26-29H,3,6,9,12H2,1-2,4H3/t15-,23+/m1/s1
⚫	| InChIKey = XRYVAQQLDYTHCL-CMJOXMDJSA-N
	| ChEMBL_Ref = {{ebicite|correct|EBI}}
⚫	| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
⚫	| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
⚫	|CASNo_Ref = {{cascite|correct|CAS}}
	| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}		| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
			| ChemSpiderID = 65766
	|SMILES=(CC=C(C)C)(Cc1c(O)cc(O)c2C(=O)C(Oc12)c1ccc(O)cc1O)C(C)=C }}		| SMILES = (CC=C(C)C)(Cc1c(O)cc(O)c2C(=O)C(Oc12)c1ccc(O)cc1O)C(C)=C
			| PubChem = 72936
		⚫	| InChI = 1/C25H28O6/c1-13(2)5-6-15(14(3)4)9-18-20(28)11-21(29)24-22(30)12-23(31-25(18)24)17-8-7-16(26)10-19(17)27/h5,7-8,10-11,15,23,26-29H,3,6,9,12H2,1-2,4H3/t15-,23+/m1/s1
			| InChIKey = XRYVAQQLDYTHCL-CMJOXMDJBK
		⚫	| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChI = 1S/C25H28O6/c1-13(2)5-6-15(14(3)4)9-18-20(28)11-21(29)24-22(30)12-23(31-25(18)24)17-8-7-16(26)10-19(17)27/h5,7-8,10-11,15,23,26-29H,3,6,9,12H2,1-2,4H3/t15-,23+/m1/s1
		⚫	| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
		⚫	| StdInChIKey = XRYVAQQLDYTHCL-CMJOXMDJSA-N
			}}
	|Section2={{Chembox Properties		|Section2={{Chembox Properties
	|Formula={{chem|C|25|H|28|O|6}}		| Formula = {{chem|C|25|H|28|O|6}}
	|MolarMass=424.48622 g/mol		| MolarMass = 424.48622 g/mol
	}}		}}
	|Section7={{Chembox Hazards		|Section7={{Chembox Hazards
		⚫	| MainHazards= No known hazards
	|EUClass=
			| HPhrases =
	|EUIndex=
			| PPhrases =
⚫	|MainHazards= No known hazards
			| GHS_ref =
	|RPhrases= }}
	|SPhrases= }}		}} }}
	'''Sophoraflavanone G'''<ref>European Bioinformatics Institute. “Sophoraflavanone G.”: www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50209 (17 Oct 2009)</ref> is a volatile ], released in to the atmosphere, soil and ground water, by members of the ] genus. Due to an increase in the rates of antibiotic-resistant bacteria, scientific efforts have focused on finding either naturally-made or genetically modified compounds that can treat and or prevent these harmful and sometimes deadly bacteria. Sophoraflavanone G, due to its use as a phytoncide, has been found to impact the growth of antibiotic-resistant bacteria and enhance the effect of currently used antibiotics.		'''Sophoraflavanone G'''<ref>{{cite web |publisher=European Bioinformatics Institute |title=Sophoraflavanone G. |url=http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50209 |date=17 October 2009 }}</ref> is a volatile ], released into the atmosphere, soil and ground water, by plants of the genus '']''. Species include ''Sophora pachycarpa'' and ''Sophora exigua'', all found to grow within the United States in a variety of soil types, within temperate conditions, no lower than 0&nbsp;°F (US zone 6 - yellow areas shown to the right). Sophoraflavanone G is released in order to protect the plant against harmful protozoa, bacteria, and fungi. Sophoraflavanone G, also called kushenin (in traditional Chinese medicinal recipes), is a ] compound.
			Due to an increase in the rates of antibiotic-resistant bacteria, scientific efforts have focused on finding either naturally-made or genetically modified compounds that can treat and or prevent these harmful and sometimes deadly bacteria. Sophoraflavanone G, in preliminary research has been found to impact the growth of antibiotic-resistant bacteria and may enhance the effect of currently used antibiotics.
	== Background information on phytoncides==
			== Flavonoids ==
	1st discovered by B.P. Tokin, the word “phytoncide” literally means, exterminated by the plant. Phytoncides are a biologically active substance of plant origin that kills or inhibits growth and development of bacteria, microscopic fungi, and protozoa. Phytoncides play an important role in plant immunity and in the relationships between organisms within an ecosystem.<ref>“Phytoncide.” The Great Soviet Encyclopedia, 3rd Edition (1970-1979). http://encyclopedia2.thefreedictionary.com/Phytoncide</ref>
		⚫	] are a class of secondary metabolites found in plants that fulfill a wide variety of functions. They are most commonly known as plant pigments in flower petals to attract pollinators and for their antioxidant activities, providing some hope for consumers regarding medicinal uses, potentially cancer treatment. It has not been until recently that their use as a phytoncide was made known.
		⚫	== Toxicity ==
	The ability to produce phytoncides is a quality common among plants. The release of phytoncides increase when a plant is injured. Phytoncide compound composition's vary depending on whether the compound is considered a ], ], or other secondary metabolites (not found in the major classes of natural compounds).<ref name="phytoncide">Duka, R., and Ardelean, D. “Phytoncides and Phytoalexins – Vegetal Antibiotics.” Jurnal Medical Aradean (Arad Medical Journal) 13 (2010): 19-25.</ref>
		⚫	No known toxicity reports against humans have been found related to phytoncides, including sophoraflavanone G.
	=== Categories of phytoncides ===
		⚫	== Potential use an antimicrobial agent against MRSA and VRE ==
	There are two categories of phytoncides: 1) Nonexcretory phytoncides (found in the protoplasma of cells) and 2) Volatile phytoncides (released in to the atmosphere, soil and water) Examples of plants releasing each type of phytoncide are: (nonexcretory)onion, garlic, and horseradish,and (volatile) pine, oak, eucalyptus, and members of the Sophora genus.<ref name="phytoncide" />]
		⚫	In result to the increasing cases of ] and ], a tremendous amount of research has gone into finding reliable methods of controlling and potentially preventing antibiotic-resistant strains of bacteria. One promising candidate for the treatment of these deadly bacteria is sophoraflavanone G. Throughout the scientific literature, it has been cited that sophoraflavanone G has had considerable success against antibiotic-resistant bacteria like ''S. aureus'' and ''Enterococci''.
	Some phytoncides effect only insects feeding on the plant, acting on the insect’s autonomic nervous system. Other phytoncides target mainly microbes. The antimicrobial potency and range of phytoncides vary greatly among species. Some can kill many types of protozoa, bacteria, fungi, and insects within minutes or seconds, while others may take hours or only harm the pest. In addition to acting as a “plant protector”, phytoncides can also impede the reproduction of pests.<ref name="phytoncide" />
		⚫	''Staphylococcus aureus'' and ''Enterococcus'' are two of the leading causes of nosocomial (contracted while in a health facility) infections in hospitals and nursing homes, and reports on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) in hospitals have increased worldwide.
	=== General effect on environment ===
	Regarding how phytoncides effect a plant’s immunity, for example, 1 hectare of pine forest will release approximately 5&nbsp;kg of volatile phytoncides in to the atmosphere in one day, reducing the amount of microflora in the air and essentially sterilizing the atmosphere among the forest, containing only about 200-300 bacterial cells/m3. This effect is found more commonly in coniferous forests as opposed to deciduous; something to consider when planning resort locations and urban landscaping.<ref name="phytoncide" />
	===General uses of phytoncides===
	Because of the antimicrobial properties of phytoncides, extensive research has been done to investigate their use in medicine, as a plant protector in greenhouses, and in the shipping and storing of perishables like fruits and vegetables.
	One volatile phytoncide, sophoraflavanone G, is of particular interest, due to its use in treating ] and ] bacteria.
	==Sophoraflavanone G==
	]
	Sophoraflavanone G is among the volatile category of phytoncides, released in to the atmosphere, soil, and ground water by the plant species '']'',<ref>Sophora flavescens - http://en.wikipedia.org/Sophora_flavescens (5 Feb 2011)</ref> ''Sophora pachycarpa'', and ''Sophora exigua''; all found to grow within the United States in a variety of soil types, within temperate conditions, no lower than 0°F (US zone 6 - yellow areas shown to the right). Sophoraflavanone G is released in order to protect the plant against harmful protozoa, bacteria, and fungi. Sophoraflavanone G, also called kushenin (in traditional Chinese medicinal recipes), is a ] compound.
	===Flavanoids===
⚫	] are a class of secondary metabolites found in plants that fulfill a wide variety of functions. They are most commonly known as plant pigments in flower petals to attract pollinators and for their antioxidant activities, providing some hope for consumers regarding medicinal uses, potentially cancer treatment. It has not been until recently that their use as a phytoncide was made known.<ref>Flavanoids - http://en.wikipedia.org/Flavonoid (8 April 2011)</ref>
⚫	=== Toxicity ===
⚫	No known toxicity reports against humans have been found related to phytoncides, including Sophoraflavanone G.
⚫	===Uses of Sophoraflavanone G: antimicrobial agent against MRSA and VRE===
⚫	In result to the increasing cases of ] and ], a tremendous amount of research has gone in to finding reliable methods of controlling and potentially preventing antibiotic-resistant strains of bacteria. One promising candidate for the treatment of these deadly bacteria is sophoraflavanone G. Throughout the scientific literature, it has been cited that sophoraflavanone G has had considerable success against antibiotic-resistant bacteria like ''S. aureus'' and ''Enterococci''.
⚫	''Staphylococcus aureus'' and ''Enterococcus'' are two of the leading causes of nosocomial (contracted while in a health facility) infections in hospitals and nursing homes, and reports on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) in hospitals have increased worldwide.
	]		]
	]		]
	MRSA involves a strain of ''Staphylococcus aureus'' bacteria that normally lives on the skin and sometimes in the nasal passages of healthy people. In addition, these particular strains of S. aureus do not respond to some of the antibiotics used to treat staph infections. The bacteria can cause infection when they enter the body through a cut, sore, catheter, or breathing tube. Once infected, the case can be minor and local, or more serious, involving complications with the major tissues within the patient, specifically heart, lungs, blood, and bone. Serious staph infections are more common in people with weak immune systems, particularly patients in hospitals and long-term healthcare facilities and those who are healthy, but otherwise in close contact with many individuals through shared use of equipment and personal items, like athletes and children in daycare.<ref name="mrsa">National Institute of Health. “Methicillin-resistant Staphylococcus aureus; Community-acquired MRSA (CA-MRSA); Hospital-acquired MRSA (HA-MRSA)” http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004520 (30 May 2009)</ref>		MRSA involves a strain of ''Staphylococcus aureus'' bacteria that normally lives on the skin and sometimes in the nasal passages of healthy people. In addition, these particular strains of S. aureus do not respond to some of the antibiotics used to treat staph infections. The bacteria can cause infection when they enter the body through a cut, sore, catheter, or breathing tube. Once infected, the case can be minor and local, or more serious, involving complications with the major tissues within the patient, specifically heart, lungs, blood, and bone. Serious staph infections are more common in people with weak immune systems, particularly patients in hospitals and long-term healthcare facilities and those who are healthy, but otherwise in close contact with many individuals through shared use of equipment and personal items, like athletes and children in daycare.<ref name="mrsa">{{cite web |publisher=National Institute of Health |title=Methicillin-resistant Staphylococcus aureus; Community-acquired MRSA (CA-MRSA); Hospital-acquired MRSA (HA-MRSA) |url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004520 |date=30 May 2009 }}</ref>
	Serious staph infections are quite difficult to treat, due to increasing numbers of antibiotic-resistant strains of ''S. aureus'' in the population. If left untreated, serious staph infections can result in organ failure and death.<ref name="mrsa" />		Serious staph infections are quite difficult to treat, due to increasing numbers of antibiotic-resistant strains of ''S. aureus'' in the population. If left untreated, serious staph infections can result in organ failure and death.<ref name="mrsa" />
	''Enterococcus'' are normally present in the human intestines, female genital tract and often within the environment. When these bacteria cause infections, usually within the urinary tract, bloodstream, or in wounds associated with catheters or surgical procedures, the common antibiotic used to treat these cases is Vancomycin. In some instances, enterococci have become resistant to this drug and are, in result, referred to as vancomycin-resistant enterococci (VRE). Most of these infections occur within the long-term healthcare setting.<ref name="cdc">Center for Disease Control and Prevention. “Healthcare-associated infections.” http://www.cdc.gov/HAI/organisms/vre/vre.html (24 Nov 2010)</ref>		''Enterococcus'' are normally present in the human intestines, female genital tract and often within the environment. When these bacteria cause infections, usually within the urinary tract, bloodstream, or in wounds associated with catheters or surgical procedures, the common antibiotic used to treat these cases is Vancomycin. In some instances, enterococci have become resistant to this drug and are, in result, referred to as vancomycin-resistant enterococci (VRE). Most of these infections occur within the long-term healthcare setting.<ref name="cdc">{{cite web |publisher=Centers for Disease Control and Prevention |title=Healthcare-associated infections |url=https://www.cdc.gov/HAI/organisms/vre/vre.html |date=24 November 2010 }}</ref>
	Serious VRE infections are common among those who have been previously treated with the antibiotic vancomycin and hospitalized for long periods of time, those who have a weak immune system, any patients who have recently undergone surgery or those individuals with medical devices that stay inside their bodies for long periods of time (mainly catheters).		Serious VRE infections are common among those who have been previously treated with the antibiotic vancomycin and hospitalized for long periods of time, those who have a weak immune system, any patients who have recently undergone surgery or those individuals with medical devices that stay inside their bodies for long periods of time (mainly catheters).
	VRE is often spread by the contaminated hands of caregivers, or directly after those infected with VRE, touch surfaces. VRE is not spread through the air by coughing or sneezing.<ref name="cdc" />		VRE is often spread by the contaminated hands of caregivers, or directly after those infected with VRE, touch surfaces. VRE is not spread through the air by coughing or sneezing.<ref name="cdc" />
	==== Research in to antimicrobial activity of Sophoraflavanone G ====		=== Research into antimicrobial activity ===
	Research conducted in Japan, in 1995, report that the use of sophoraflavanone G completely inhibits the growth of 21 strains of methicillin-resistant ''S. aureus'' at concentrations of 3.13-6.25&nbsp;ug/mL. When this compound is combined with vancomycin, minocycline, and rifampicin, the rates of inhibition increased, indicating a partially synergistic effect with anti-MRSA antibiotics (Sato et al).<ref>Sato, M., Tsuchiya, H., Takase, I., Kureshiro, H., Tanigaki, S. and Iinuma, M. “Antibacterial activity of flavanone isolated from Sophora exigua against methicillin-resistant Staphylococcus aureus and its combination with antibiotics.” Phytotherapy Research 9 (1995): 509–512.</ref> Similarly in Iran, in 2006, a research group reported that the antibacterial activity of gentamycin was enhanced through the use of sophoraflavanone G, citing that bacterial colonies of ''Staphylococcus aureus'', on TLC plates showed significant decrease (4x) in growth while in the presence of small amounts (.03&nbsp;ug/mL) of this compound (Fakhimi et al).<ref>Fakhimi A, Iranshahi M, Emami SA, Amin-Ar-Ramimeh E, Zarrini G, Shahverdi AR. “Sophoraflavanone G from sophora pachycarpa enhanced the antibacterial activity of gentamycin against Staphylococcus aureus.” Zeitschrift fur Naturforschung C. (Journal of Biosciences) Sep-Oct(9-10) 2006:769-72</ref> Additional studies, done in South Korea in 2009 and Romania in 2010, support these findings of partially synergistic effects between sophoraflavanone G and various antibiotics, adding that when used either alone, or in conjunction with ampicillin and oxacillin (Cha et al),<ref>Cha J., Moon S., Kim J., Jung E., Lee Y. “Antibacterial activity of sophoraflavanone G isolated from the roots of sophora flavescens against methicillin-resistant staphylococcus aureus.” Phytotherapy Research 23 Sep(9) 2009: 1326-31.</ref> and ampicillin, gentamycin, minocycline, vancomycin, and hydrochloride (Duka et al), sophoraflavanone G increases the number of antibiotic-resistant bacteria (MRSA & VRE) killed within plated colonies (based on FIC indices).		Research conducted in Japan, in 1995, report that the use of sophoraflavanone G completely inhibits the growth of 21 strains of methicillin-resistant ''S.&nbsp;aureus'' at concentrations of 3.13-6.25&nbsp;μg/mL. When this compound is combined with ], ], and ], the rates of inhibition increased, indicating a partially synergistic effect with anti-MRSA antibiotics.<ref>Sato, M., Tsuchiya, H., Takase, I., Kureshiro, H., Tanigaki, S. and Iinuma, M. “Antibacterial activity of flavanone isolated from Sophora exigua against methicillin-resistant Staphylococcus aureus and its combination with antibiotics.” Phytotherapy Research 9 (1995): 509–512.</ref> Similarly in Iran, in 2006, a research group reported that the antibacterial activity of ] was enhanced through the use of sophoraflavanone G, citing that bacterial colonies of ''S.&nbsp;aureus'', on TLC plates showed a significant decrease (4x) in growth while in the presence of small amounts (.03&nbsp;μg/mL) of this compound.<ref>Fakhimi A, Iranshahi M, Emami SA, Amin-Ar-Ramimeh E, Zarrini G, Shahverdi AR. “Sophoraflavanone G from Sophora pachycarpa enhanced the antibacterial activity of gentamycin against Staphylococcus aureus.” Zeitschrift für Naturforschung C. (Journal of Biosciences) Sep-Oct(9-10) 2006:769-72</ref> Additional studies, done in South Korea in 2009 and Romania in 2010, support these findings of partially synergistic effects between sophoraflavanone G and various antibiotics, adding that when used either alone, or in conjunction with ] and ],<ref>Cha J., Moon S., Kim J., Jung E., Lee Y. “Antibacterial activity of sophoraflavanone G isolated from the roots of sophora flavescens against methicillin-resistant staphylococcus aureus.” Phytotherapy Research 23 Sep(9) 2009: 1326-31.</ref> and ampicillin, gentamicin, ], and vancomycin hydrochloride,<ref name="phytoncide">Duka, R., and Ardelean, D. “Phytoncides and Phytoalexins – Vegetal Antibiotics.” Jurnal Medical Aradean (Arad Medical Journal) 13 (2010): 19-25.</ref> sophoraflavanone G increases the number of antibiotic-resistant bacteria (MRSA & VRE) killed within plated colonies (based on FIC indices).
	==== Additional uses of Sophoraflavanone G ====		=== Additional uses ===
	In addition to the use of sophoraflavanone G as treatment against bacteria and other microflora present within the environment, by plants and humans alike, this compound has also been reported to be useful in the treatment of a variety of maladies, ranging from Eicosanoid-related skin inflammation such as ], to treating more serious medical issues like ] and ].		In addition to the use of sophoraflavanone G as treatment against bacteria and other microflora present within the environment, by plants and humans alike, this compound has also been reported to be useful in the treatment of a variety of maladies, ranging from eicosanoid-related skin inflammation such as ], to treating more serious medical issues like ] and ].
	<gallery>
		⚫	Regarding anti-inflammatory treatments, sophoraflavanone G inhibits eicosanoid generating enzymes, and prostaglandin production, suggesting its potential use for eicosanoid-related skin inflammation such as atopic dermatitis.<ref>Kim D., Chi Y., Son K., Chang H., Kim J., Kang S., and Kim H. “Effects of sophoraflavanone G, a prenylated flavonoid from Sophora flavescens on cyclooxygenase-2 and in vivo inflammatory response.” Archives of Pharmacal Research Jun 25(3) 2002:329-35.</ref> In 2004, Youn et al. reported that sophoraflavanone G (in addition to other flavanoids) showed moderate anti-malarial activities based on the EC50 values within mice populations, potentially due to methoxyl groups found within the structure.<ref>Youn Chul Kim, Hye-Sook Kim, Yusuke Wataya, Dong Hwan Sohn, Tai Hyun Kang, Myung Soo Kim, Yong Man Kim, Geon-Mok Lee, Jong-Duk Chang and Hyun Park, “Antimalarial Activity of Lavandulyl Flavanones Isolated from the Roots of Sophora flavescens”, Biological & Pharmaceutical Bulletin 27 (2004): 748-750.</ref> In addition, sophoraflavanone G may have implications for the treatment of myeloid leukemia because sophoraflavanone G exhibits cytotoxic activity against human myeloid leukemia HL-60 cells.<ref>Tai-Hyun Kang, Sei-Joon Jeong, Won-Gil Ko, Na-Young Kim, Byung-Hoon Lee, Masanori Inagaki, Tomofumi Miyamoto, Ryuichi Higuchi, and Youn-Chul Kim. “Cytotoxic Lavandulyl Flavanones from Sophora flavescens.” Journal of Natural Products 5 (2000):680–681.</ref>
	File:Atopic dermatitis.png|A child with atopic dermatitis
	File:Malaria.jpg|''Plasmodium'' sporozoite traverses the cytoplasm of a mosquito midgut epithelial cell
	File:Plasmodium.jpg|''Plasmodium within blood after contraction of malaria''
	File:Auer_rods.PNG|Acute myeloid leukemia, showing characteristic growth of abnormal white blood cells
	</gallery>
⚫	Regarding anti-inflammatory treatments, research by Kim et al (2002) reported that sophoraflavanone G inhibited eicosanoid generating enzymes, and prostaglandin production, suggesting its potential use for eicosanoid-related skin inflammation such as atopic dermatitis.<ref>Kim D., Chi Y., Son K., Chang H., Kim J., Kang S., and Kim H. “Effects of sophoraflavanone G, a prenylated flavonoid from Sophora flavescens on cyclooxygenase-2 and in vivo inflammatory response.” Archives of Pharmacal Research Jun 25(3) 2002:329-35.</ref> In 2004, Youn et al reported that sophoraflavanone G (in addition to other flavanoids) showed moderate anti-malarial activities based on the EC50 values within mice populations, potentially due to methoxyl groups found within the structure.<ref>Youn Chul Kim, Hye-Sook Kim, Yusuke Wataya, Dong Hwan Sohn, Tai Hyun Kang, Myung Soo Kim, Yong Man Kim, Geon-Mok Lee, Jong-Duk Chang and Hyun Park, “Antimalarial Activity of Lavandulyl Flavanones Isolated from the Roots of Sophora flavescens”, Biological & Pharmaceutical Bulletin 27 (2004): 748-750.</ref> In addition, sophoraflavanone G has also been said to have implications for the treatment of myeloid leukemia, based on the research findings of Kang et al (2000), who reported that sophoraflavanone G exhibited cytotoxic activity against human myeloid leukemia HL-60 cells.<ref>Tai-Hyun Kang, Sei-Joon Jeong, Won-Gil Ko, Na-Young Kim, Byung-Hoon Lee, Masanori Inagaki, Tomofumi Miyamoto, Ryuichi Higuchi, and Youn-Chul Kim. “Cytotoxic Lavandulyl Flavanones from Sophora flavescens.” Journal of Natural Products 5 (2000):680–681.</ref>
	== References ==		== References ==
	<references/>		<references/>
			{{Flavanone}}
⚫	]
		⚫	]
	]		]
	]		]
	]